
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines, a commercial-stage biotechnology company specializing in oncology therapeutics, is positioned for sustained growth, bolstered by its leading drug, Brukinsa, which holds a significant share of over 60% in company revenue and has strong market preference among key opinion leaders. The company's unique CRO-free strategy enhances its operational efficiency, allowing it to run global trials independently, which may lead to improved financial performance and a path toward positive free cash flow by 2025. Projections indicate robust annual growth exceeding 40% and an estimated peak sales potential of approximately $7.1 billion by 2034, underscoring BeOne's competitive advantage and favorable market dynamics.
Bears say
BeOne Medicines faces a negative outlook primarily due to significant risks tied to its reliance on Brukinsa, which constitutes over 60% of the company's revenue; any pressures on this key product could lead to substantial downside. Additionally, the company confronts challenges such as slower-than-expected uptake of its commercial products, potential delays in clinical trials, and risks associated with its crowded oncology market, where competition for next-generation therapies is intense. Furthermore, the perception of geopolitical risks related to its Chinese origins, combined with considerable cash burn on its pipeline that may not yield marketable drugs, threatens the overall financial stability and competitive positioning of BeOne Medicines.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares